Evidence map›Paper›PMID 31865785›Full record

Trial reportHypertension (Dallas, Tex. : 1979)2020

Estimated Stroke-Free Survival of Folic Acid Therapy for Hypertensive Adults: Projection Based on the CSPPT.

Tiantian Zhang, Tengfei Lin, Yang Wang, Binyan Wang, Xianhui Qin, Feng Xie, Yimin Cui, Yong Huo, Xiaobin Wang, Zugui Zhang and 1 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Hypertension (Dallas, Tex. : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. The feasibility of polypill for cardiovascular disease prevention in Asian Population.Journal of clinical hypertension (Greenwich, Conn.) · 2021
    Review
  4. Hypertension and stroke in Asia: A comprehensive review from HOPE Asia.Journal of clinical hypertension (Greenwich, Conn.) · 2021
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Tiantian ZhangFrom the College of Pharmacy (T.Z., T.L., J.J.), Jinan University, Guangzhou, China.
Tengfei LinFrom the College of Pharmacy (T.Z., T.L., J.J.), Jinan University, Guangzhou, China.
Yang WangDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, CA (Y.W.).
Binyan WangNational Clinical Research Study Center for Kidney Disease; the State Key Laboratory for Organ Failure Research; Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, China (B.W., X.Q.).
Xianhui QinNational Clinical Research Study Center for Kidney Disease; the State Key Laboratory for Organ Failure Research; Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, China (B.W., X.Q.).
Feng XieDepartment of Clinical Epidemiology and Biostatistics (F.X.).
Yimin CuiDepartment of Pharmacy (Y.C.), Peking University First Hospital, Beijing, China.
Yong HuoDepartment of Cardiology (Y.H.), Peking University First Hospital, Beijing, China.
Xiaobin WangDepartment of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland (X.W.).
Zugui ZhangChristiana Care Health System, Newark, Delaware (Z.Z.).
Jie JiangFrom the College of Pharmacy (T.Z., T.L., J.J.), Jinan University, Guangzhou, China.
Jinan University · CNNational Clinical Research · USPeking University · CNChina Agricultural University · CNJohns Hopkins University · USMcMaster University · CAUniversity of California, Los Angeles · US

Funding

Subproject Title: Clinical Research Education, Mentoring and Career Development CoreU54GM104941 · NIGMS · UNIVERSITY OF DELAWARE · PI Gregory E Hicks · 2013 to 2026
$60.5M
NIGMS NIH HHS U54 GM104941
6 · The paper itself

Abstract

The CSPPT (China Stroke Primary Prevention Trial) demonstrated a significant risk reduction of first stroke in hypertensive patients treated with enalapril plus folic acid compared with those with enalapril alone, but the lifetime stroke-free survival associated with the treatment is unknown. By establishing adjusted models for competing risks and an age-based time scale using data from 19 053 participants of the CSPPT, we estimated lifetime incremental stroke-free survival for enalapril-folic acid versus enalapril alone. Compared with enalapril alone, the enalapril plus folic acid treatment projected a mean lifetime stroke-free survival gain of 1.75 months, with an interquartile range from 0.73 to 2.39 months and the maximum gain up to 12.95 months. Subgroup analyses showed greater gain in stroke-free survival in younger, male patients, those with lower baseline folate levels, higher baseline systolic blood pressure, higher baseline total cholesterol and blood glucose, and with MTHFR (methylenetetrahydrofolate reductase) C677T CT or TT genotype. Overall, besides significant benefit in certain subgroups, enalapril plus folic acid treatment for hypertensive patients is associated with a modest gain in lifetime stroke-free survival, compared with enalapril alone.

Indexed as

AgedBlood PressureDisease-Free SurvivalDouble-Blind MethodFemaleFolic AcidFollow-Up StudiesHumansHypertensionMaleMiddle AgedPrimary PreventionStrokeTreatment OutcomeVitamin B ComplexFolic AcidVitamin B Complexfolic acidhypertensionlife expectancyprimary preventionstroke

Identifiers

PMID31865785
PMCPMC8020900
OpenAlexW2996875402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.